Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05050799 · ClinicalTrials.gov registry record

US Post-Market Surveillance Study of the Surfacer System

A clinical trial of Venous Disease, sponsored by Merit Medical Systems.

Recruiting
Registry status
30
Enrollment target
6
Study locations

NCT05050799 is a study of Venous Disease that is actively recruiting participants, run by Merit Medical Systems. The registered enrollment target is 30 participants, below the 206-participant average among 6 other Venous Disease trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05050799, a study of Venous Disease, is actively recruiting participants, sponsored by Merit Medical Systems.

RECRUITING
Registry status
30 participants
Enrollment target
6
Study locations

Study Summary

Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.

Conditions Studied

Interventions

  • DEVICE Central Venous Access

Study Locations (6)

Texas

  • Baylor Scott & White Heart and Vascular Hospital - Dallas
  • The University of Texas Health Science Center at Houston - Houston
  • Flow Vascular Institute - Pasadena

Arizona

  • Pima Heart and Vascular - Tucson

Florida

  • Sarasota Memorial Health Care System - Sarasota

Utah

  • St. Mark's Hospital - Millcreek

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-02-08
Est. Completion 2026-12-15

Sponsor

Merit Medical Systems

18 total trials

What the Registry Record Tells You About NCT05050799

The ClinicalTrials.gov registry entry for NCT05050799 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 6 other Venous Disease trials with a reported enrollment target (85% lower). The listed sponsor is Merit Medical Systems, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Venous Disease appearing as the primary indexed condition, and to 1 intervention - of which Central Venous Access is the first listed.

NCT05050799 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Texas, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT05050799 about?

NCT05050799 is a clinical study titled "US Post-Market Surveillance Study of the Surfacer System". Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements de...

What is the current status of trial NCT05050799?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2022-02-08. Estimated completion is 2026-12-15.

What conditions does trial NCT05050799 study?

This clinical trial studies the following conditions: Venous Disease.

What interventions are being tested in trial NCT05050799?

The interventions under investigation include: Central Venous Access (DEVICE).

Who is sponsoring clinical trial NCT05050799?

This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05050799 being conducted?

This trial has 6 study locations across Arizona, Florida, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.